Changes in nephrogenous cyclic AMP excretion and plasma cyclic AMP following treatment of hyperthyroidism. 1984

M A Naafs, and P C van der Velden, and H R Fischer, and G Koorevaar, and S van Duin, and W H Hackeng, and W Schopman, and J Silberbusch

Plasma cyclic AMP (PcAMP) concentration and the excretion of cyclic AMP/dl GF were estimated in 11 thyrotoxic patients before and after medical treatment. PcAMP concentrations were significantly higher during hyperthyroidism (2.30 +/- 0.69 vs 1.88 +/- 0.71 nmol/dl; P less than 0.05), and total urinary cyclic AMP (TcAMP) excretion showed no significant changes (3.24 +/- 0.64 vs 3.44 +/- 1.77 nmol/dl GF). Nephrogenous (NcAMP) excretion rose significantly (1.00 +/- 0.82 vs 1.68 +/- 1.31 mmol/dl GF; P less than 0.025). The increase in NcAMP excretion correlated significantly with the decrease in serum T3 levels (r = -0.46; P less than 0.05). Serum iPTH levels showed no significant change. Both the serum Ca, corrected for serum total protein and TmPO4/GFR declined after treatment (respectively 2.44 +/- 0.13 vs 2.33 +/- 0.08 mmol/l; P less than 0.05 and 1.18 +/- 0.29 vs 1.05 +/- 0.22 mmol/l; P less than 0.05). It is concluded that the rise in NcAMP excretion corroborates the concept of increasing parathyroid activity following the treatment of hyperthyroidism.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010280 Parathyroid Glands Two pairs of small oval-shaped glands located in the front and the base of the NECK and adjacent to the two lobes of THYROID GLAND. They secrete PARATHYROID HORMONE that regulates the balance of CALCIUM; PHOSPHORUS; and MAGNESIUM in the body. Gland, Parathyroid,Glands, Parathyroid,Parathyroid Gland
D005260 Female Females
D005919 Glomerular Filtration Rate The volume of water filtered out of plasma through glomerular capillary walls into Bowman's capsules per unit of time. It is considered to be equivalent to INULIN clearance. Filtration Rate, Glomerular,Filtration Rates, Glomerular,Glomerular Filtration Rates,Rate, Glomerular Filtration,Rates, Glomerular Filtration
D006044 Goiter, Nodular An enlarged THYROID GLAND containing multiple nodules (THYROID NODULE), usually resulting from recurrent thyroid HYPERPLASIA and involution over many years to produce the irregular enlargement. Multinodular goiters may be nontoxic or may induce THYROTOXICOSIS. Nodular Goiter,Goiters, Nodular,Nodular Goiters
D006111 Graves Disease A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy). Basedow's Disease,Exophthalmic Goiter,Goiter, Exophthalmic,Graves' Disease,Basedow Disease,Hyperthyroidism, Autoimmune,Basedows Disease,Disease, Basedow,Disease, Basedow's,Disease, Graves,Disease, Graves',Exophthalmic Goiters,Goiters, Exophthalmic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000242 Cyclic AMP An adenine nucleotide containing one phosphate group which is esterified to both the 3'- and 5'-positions of the sugar moiety. It is a second messenger and a key intracellular regulator, functioning as a mediator of activity for a number of hormones, including epinephrine, glucagon, and ACTH. Adenosine Cyclic 3',5'-Monophosphate,Adenosine Cyclic 3,5 Monophosphate,Adenosine Cyclic Monophosphate,Adenosine Cyclic-3',5'-Monophosphate,Cyclic AMP, (R)-Isomer,Cyclic AMP, Disodium Salt,Cyclic AMP, Monoammonium Salt,Cyclic AMP, Monopotassium Salt,Cyclic AMP, Monosodium Salt,Cyclic AMP, Sodium Salt,3',5'-Monophosphate, Adenosine Cyclic,AMP, Cyclic,Adenosine Cyclic 3',5' Monophosphate,Cyclic 3',5'-Monophosphate, Adenosine,Cyclic Monophosphate, Adenosine,Cyclic-3',5'-Monophosphate, Adenosine,Monophosphate, Adenosine Cyclic

Related Publications

M A Naafs, and P C van der Velden, and H R Fischer, and G Koorevaar, and S van Duin, and W H Hackeng, and W Schopman, and J Silberbusch
January 1981, Recent progress in hormone research,
M A Naafs, and P C van der Velden, and H R Fischer, and G Koorevaar, and S van Duin, and W H Hackeng, and W Schopman, and J Silberbusch
July 1988, Bone and mineral,
M A Naafs, and P C van der Velden, and H R Fischer, and G Koorevaar, and S van Duin, and W H Hackeng, and W Schopman, and J Silberbusch
September 1985, Nihon Naibunpi Gakkai zasshi,
M A Naafs, and P C van der Velden, and H R Fischer, and G Koorevaar, and S van Duin, and W H Hackeng, and W Schopman, and J Silberbusch
December 1980, Endocrinology,
M A Naafs, and P C van der Velden, and H R Fischer, and G Koorevaar, and S van Duin, and W H Hackeng, and W Schopman, and J Silberbusch
October 1976, Archives of internal medicine,
M A Naafs, and P C van der Velden, and H R Fischer, and G Koorevaar, and S van Duin, and W H Hackeng, and W Schopman, and J Silberbusch
June 1984, European journal of clinical investigation,
M A Naafs, and P C van der Velden, and H R Fischer, and G Koorevaar, and S van Duin, and W H Hackeng, and W Schopman, and J Silberbusch
May 1981, Biochemical and biophysical research communications,
M A Naafs, and P C van der Velden, and H R Fischer, and G Koorevaar, and S van Duin, and W H Hackeng, and W Schopman, and J Silberbusch
June 1980, Nihon Naibunpi Gakkai zasshi,
M A Naafs, and P C van der Velden, and H R Fischer, and G Koorevaar, and S van Duin, and W H Hackeng, and W Schopman, and J Silberbusch
January 1979, Nephron,
M A Naafs, and P C van der Velden, and H R Fischer, and G Koorevaar, and S van Duin, and W H Hackeng, and W Schopman, and J Silberbusch
January 1980, Archivos de investigacion medica,
Copied contents to your clipboard!